SBIR/STTR Reauthorization Stalls in Senate

The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, known as "America's Seed Fund," collectively represent the largest source of early-stage, high-risk technology financing in the United States. Federal agencies with extramural research and development budgets exceeding $100 million are required to allocate 3.2% of those funds to the SBIR program, with agencies having over $1 billion in R&D budgets setting aside an additional 0.45% for STTR. Annually, this amounts to over $4 billion in non-dilutive funding for startups and small businesses. Established by the Small Business Innovation Development Act of 1982, the SBIR program's primary goals are to stimulate technological innovation, use small businesses to meet federal R&D needs, and increase the private sector's commercialization of technology developed from federal funding. The STTR program, created in 1992, shares these objectives but mandates a formal collaboration between the small business and a non-profit U.S. research institution. For many startups, these programs bridge the critical funding gap between initial research and viable commercial products, often referred to as the "valley of death." The current legislative impasse is not unprecedented. The programs have faced previous reauthorization delays, including a significant two-year gap between 2009 and 2011. The present deadlock stems from competing legislative proposals in the Senate. Senator Joni Ernst has advocated for reforms in the INNOVATE Act, which proposes lifetime funding caps to prevent companies from becoming "SBIR mills" and measures to counter foreign influence. In contrast, a bill co-sponsored by Senator Edward Markey, the "SBIR/STTR Reauthorization Act of 2025," seeks to make the programs permanent, arguing this would provide stability for long-term R&D planning. A lapse in authorization means that while agencies have the allocated funds, they cannot issue new solicitations or awards for Phase I or Phase II projects. Ongoing projects can continue using previously obligated funds, but administrative actions and new funding increments face significant delays. This pause creates an "existential threat" for the thousands of small firms that structure their R&D cycles around the regular release of SBIR/STTR funding topics. The economic impact of this stalemate is substantial. For every dollar invested, the SBIR/STTR programs have been estimated to return between $22 and $33 in economic benefits. Over their history, the programs have provided more than $77 billion to 33,000 businesses. The Department of Defense, the largest participant, stands to lose or delay over $1.6 billion in investments for warfighter technology, while the National Institutes of Health could see more than $1.2 billion in funding for early-stage life science research disrupted. Recent negotiations between Senators Joni Ernst and Ed Markey have resulted in a compromise bill, the "Small Business Innovation and Economic Security Act." This new legislation, which would reauthorize the programs for five years, is expected to pass the Senate and House. The bill reportedly includes provisions to safeguard technology from foreign influence and establishes a "Strategic Breakthrough" initiative to help companies bridge the gap between development and production. While the legislative process moves forward, the shutdown has forced companies to adapt. Experts recommend pursuing Phase III awards, which are follow-on production contracts and not new grants, as they can still proceed. Companies are also encouraged to explore alternative federal funding vehicles, such as grants from the Advanced Research Projects Agency-Energy (ARPA-E) or Broad Agency Announcements (BAAs) from agencies like DARPA, which continue to fund innovation through different channels. State-level economic development grants and private accelerators also offer non-dilutive funding opportunities.